BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

26 related articles for article (PubMed ID: 29235893)

  • 1. Development of 3-methyl/3-(morpholinomethyl)benzofuran derivatives as novel antitumor agents towards non-small cell lung cancer cells.
    Al-Sanea MM; Al-Ansary GH; Elsayed ZM; Maklad RM; Elkaeed EB; Abdelgawad MA; Bukhari SNA; Abdel-Aziz MM; Suliman H; Eldehna WM
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):987-999. PubMed ID: 33985397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The cytotoxic effect of 2-acylated-1,4-naphthohydroquinones on leukemia/lymphoma cells.
    Pedroza DA; De Leon F; Varela-Ramirez A; Lema C; Aguilera RJ; Mito S
    Bioorg Med Chem; 2014 Jan; 22(2):842-7. PubMed ID: 24368029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploring Aurone Derivatives as Potential Human Pancreatic Lipase Inhibitors through Molecular Docking and Molecular Dynamics Simulations.
    Nguyen PTV; Huynh HA; Truong DV; Tran TD; Vo CT
    Molecules; 2020 Oct; 25(20):. PubMed ID: 33066044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Melding of Drug Screening Platforms for Melanoma.
    Couto GK; Segatto NV; Oliveira TL; Seixas FK; Schachtschneider KM; Collares T
    Front Oncol; 2019; 9():512. PubMed ID: 31293965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and anti-cancer activity evaluation of new aurone derivatives.
    Demirayak S; Yurttas L; Gundogdu-Karaburun N; Karaburun AC; Kayagil I
    J Enzyme Inhib Med Chem; 2015; 30(5):816-25. PubMed ID: 25716125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis, cytotoxicity, and molecular docking of substituted 3-(2-methylbenzofuran-3-yl)-5-(phenoxymethyl)-1,2,4-oxadiazoles.
    Mokenapelli S; Thalari G; Vadiyaala N; Yerrabelli JR; Irlapati VK; Gorityala N; Sagurthi SR; Chitneni PR
    Arch Pharm (Weinheim); 2020 Jun; 353(6):e2000006. PubMed ID: 32309890
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of Fourteen Aurone Derivatives as Potential Anti-Cancer Agents.
    Alsaif G; Almosnid N; Hawkins I; Taylor Z; Knott DLT; Handy S; Altman E; Gao Y
    Curr Pharm Biotechnol; 2017; 18(5):384-390. PubMed ID: 28464771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis, biological evaluation and molecular docking studies of novel benzofuran-pyrazole derivatives as anticancer agents.
    Abd El-Karim SS; Anwar MM; Mohamed NA; Nasr T; Elseginy SA
    Bioorg Chem; 2015 Dec; 63():1-12. PubMed ID: 26368040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis, molecular properties prediction and cytotoxic screening of 3-(2-aryl-2-oxoethyl)isobenzofuran-1(3H)-ones.
    da Silva Maia AF; Siqueira RP; de Oliveira FM; Ferreira JG; da Silva SF; Caiuby CAD; de Oliveira LL; de Paula SO; Souza RAC; Guilardi S; Bressan GC; Teixeira RR
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2810-2816. PubMed ID: 27155902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Construction of some cytotoxic agents with aurone and furoaurone scaffolds.
    Hassan GS; Georgey HH; George RF; Mohammed ER
    Future Med Chem; 2018 Jan; 10(1):27-52. PubMed ID: 29235893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aurone: A biologically attractive scaffold as anticancer agent.
    Alsayari A; Muhsinah AB; Hassan MZ; Ahsan MJ; Alshehri JA; Begum N
    Eur J Med Chem; 2019 Mar; 166():417-431. PubMed ID: 30739824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential of cyclopenta[b]benzofurans from Aglaia species in cancer chemotherapy.
    Kim S; Salim AA; Swanson SM; Kinghorn AD
    Anticancer Agents Med Chem; 2006 Jul; 6(4):319-45. PubMed ID: 16842234
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.